$796.73 Million in Sales Expected for Charles River Laboratories International, Inc. (NYSE:CRL) This Quarter

Equities analysts expect that Charles River Laboratories International, Inc. (NYSE:CRL) will post sales of $796.73 million for the current quarter, Zacks reports. Seven analysts have provided estimates for Charles River Laboratories International’s earnings, with estimates ranging from $790.30 million to $808.71 million. Charles River Laboratories International posted sales of $707.06 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 12.7%. The business is expected to issue its next earnings results on Thursday, May 6th.

On average, analysts expect that Charles River Laboratories International will report full year sales of $3.39 billion for the current financial year, with estimates ranging from $3.31 billion to $3.44 billion. For the next financial year, analysts forecast that the company will report sales of $3.75 billion, with estimates ranging from $3.60 billion to $3.90 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Charles River Laboratories International.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Tuesday, February 16th. The medical research company reported $2.39 EPS for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.28. Charles River Laboratories International had a net margin of 10.68% and a return on equity of 22.41%.

Several equities research analysts have issued reports on CRL shares. Morgan Stanley lifted their price target on Charles River Laboratories International from $245.00 to $260.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Truist boosted their target price on Charles River Laboratories International from $256.00 to $324.00 in a research report on Thursday, February 18th. Argus increased their price target on shares of Charles River Laboratories International from $235.00 to $265.00 and gave the company a “buy” rating in a research report on Tuesday, December 22nd. Smith Barney Citigroup lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a report on Wednesday, December 16th. Finally, KeyCorp upped their price objective on shares of Charles River Laboratories International from $233.00 to $256.00 and gave the company an “overweight” rating in a research note on Tuesday, November 24th. Five research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $237.41.

In other news, CEO James C. Foster sold 30,000 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 11th. The stock was sold at an average price of $285.02, for a total value of $8,550,600.00. Following the sale, the chief executive officer now directly owns 255,041 shares in the company, valued at approximately $72,691,785.82. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Michael Gunnar Knell sold 410 shares of the firm’s stock in a transaction on Friday, February 19th. The stock was sold at an average price of $290.99, for a total value of $119,305.90. Following the completion of the sale, the chief accounting officer now directly owns 4,198 shares of the company’s stock, valued at approximately $1,221,576.02. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,741 shares of company stock worth $11,677,915. 1.90% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the company. Altshuler Shaham Ltd purchased a new position in shares of Charles River Laboratories International during the third quarter valued at about $28,000. Jeppson Wealth Management LLC purchased a new stake in Charles River Laboratories International in the third quarter worth about $29,000. Trust Co. of Vermont bought a new stake in Charles River Laboratories International during the 3rd quarter valued at approximately $31,000. Berman Capital Advisors LLC grew its holdings in shares of Charles River Laboratories International by 42.6% during the 4th quarter. Berman Capital Advisors LLC now owns 144 shares of the medical research company’s stock worth $34,000 after acquiring an additional 43 shares during the period. Finally, Archer Investment Corp bought a new position in shares of Charles River Laboratories International in the 4th quarter worth approximately $38,000. 92.30% of the stock is owned by hedge funds and other institutional investors.

CRL traded down $0.84 during trading on Thursday, reaching $282.75. The stock had a trading volume of 10,504 shares, compared to its average volume of 342,970. The business has a 50-day moving average of $274.86 and a 200-day moving average of $241.52. Charles River Laboratories International has a one year low of $95.58 and a one year high of $303.79. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.22 and a current ratio of 1.45. The stock has a market cap of $14.07 billion, a PE ratio of 47.27, a PEG ratio of 2.19 and a beta of 1.12.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: Percentage Decliners

Get a free copy of the Zacks research report on Charles River Laboratories International (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.